Neurodiagnostics Market Report 2025

This Neurodiagnostics market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The neurodiagnostics market size has grown strongly in recent years. It will grow from $9.17 billion in 2024 to $9.82 billion in 2025 at a compound annual growth rate (CAGR) of 7.1%. The growth during the historic period can be attributed to factors such as the rising prevalence of neurological disorders, increased adoption of advanced imaging technologies, the growing geriatric population, heightened awareness of early disease diagnosis, expanding healthcare infrastructure, and increased investments in neuroscience research and development.

The neurodiagnostics market size is expected to see strong growth in the next few years. It will grow to $12.79 billion in 2029 at a compound annual growth rate (CAGR) of 6.8%. For the forecast period, growth is expected due to the rising demand for non-invasive diagnostic techniques, the growing prevalence of neurological disorders, higher government investments in healthcare infrastructure, increased awareness and early detection initiatives, and the expansion of personalized medicine approaches. Key trends during this period include the development of portable EEG devices, integration of AI for improved diagnostic accuracy, advancements in MRI technologies for brain imaging, the adoption of wearables for continuous monitoring, advancements in neurogenetic testing, and the use of real-time data analytics for personalized treatment plans.

The growing prevalence of neurological disorders is expected to propel the expansion of the neurodiagnostics market. Neurological disorders, which affect the brain, spinal cord, or nerves, result in various cognitive, motor, and sensory impairments. The increase in these disorders is primarily attributed to factors such as aging populations, environmental influences, lifestyle changes, genetics, and improvements in diagnostic techniques. Neurodiagnostics are crucial for the accurate identification, assessment, and monitoring of these conditions, helping ensure precise diagnoses, informed treatment choices, and effective management of neurological issues. For instance, in April 2023, the National Library of Medicine reported that 6.7 million Americans were living with Alzheimer's disease, a number expected to rise to 13.8 million by 2060. This growing prevalence of neurological conditions is driving the neurodiagnostics market forward.

Companies in the neurodiagnostics market are focusing on technological innovations, including advanced software algorithms, to enhance diagnostic accuracy and improve patient outcomes. These sophisticated algorithms use artificial intelligence (AI) and machine learning techniques to process and analyze data, supporting better decision-making and diagnostics. For example, in October 2023, Ceribell Inc., a US-based medical equipment company, launched the ClarityPro AI algorithm, which represents a significant advancement in diagnosing electrographic status epilepticus (ESE). This advanced software, integrated with the Ceribell EEG system, uses machine learning to analyze EEG waveforms and provide real-time alerts for suspected seizures. ClarityPro is the first acute care device to receive FDA clearance for standalone diagnosis, helping clinicians make quicker, more informed treatment decisions by continuously monitoring brain activity and providing actionable insights.

In July 2022, ArchiMed SAS, a France-based investment firm focused on the healthcare sector, acquired Natus Medical Incorporated for $1.1 billion. This acquisition enhances ArchiMed's position in the neurodiagnostics space by leveraging Natus Medical's expertise in developing medical devices for screening, diagnosing, and treating neurological disorders.

Major players in the neurodiagnostics market are Nihon Kohden Corporation, Cephalon LLC, Stratus Neuro LLC, Cadwell Industries Inc., Compumedics Limited, Ceribell Inc., CND Life Sciences Inc., Lifelines Neuro Inc., ANT Neuro B.V., Neurovative Diagnostics LLC, Firefly Neuroscience Inc, IntraNerve Neuroscience Inc, NeuroDiagnostics Laboratories LLC, Advanced Brain Monitoring Inc, Spes Medica S.r.l., BioSignal Group Inc, Combinostics Inc., Deymed Diagnostic LLC, NeuLine Health Inc., Ridge Diagnostics Inc., Beacon Biosignals Inc., and Intch Inc.

North America was the largest region in the neurodiagnostics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in neurodiagnostics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the neurodiagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Neurodiagnostics is a medical field focused on diagnosing and monitoring disorders of the nervous system, which includes the brain, spinal cord, and peripheral nerves. It utilizes advanced technologies and tests to evaluate neurological function, detect abnormalities, and help diagnose conditions such as epilepsy, stroke, multiple sclerosis, neuropathies, and other neurological diseases.

The primary types of neurodiagnostic tools are diagnostic and imaging solutions, as well as in-vitro diagnostics. Diagnostic and imaging solutions include medical technologies and services designed to detect health conditions through various imaging techniques and diagnostic tools. Key technologies in this area include neuroimaging, computed tomography (CT), magnetic resonance imaging (MRI), nuclear medicine imaging (PET, SPECT), near-infrared spectroscopic imaging (NIRS), electroencephalography (EEG), magnetoencephalography (MEG), voxel-based morphometry (VBM), and neuroinformatics. These diagnostic tools are vital for treating conditions such as epilepsy, Alzheimer's disease, Parkinson's disease, stroke, joint health problems, and more, and are used in hospitals, clinics, diagnostic laboratories, imaging centers, and other healthcare settings.

The neurodiagnostic market research report is one of a series of new reports that provides neurodiagnostic market statistics, including the neurodiagnostic industry's global market size, regional shares, competitors with a neurodiagnostic market share, detailed neurodiagnostic market segments, market trends and opportunities, and any further data you may need to thrive in the neurodiagnostic industry. This neurodiagnostic market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The neurodiagnostics market includes revenues earned by entities by providing services such as electroencephalography (EEG), positron emission tomography (PET), cerebrospinal fluid (CSF) analysis, and sleep apnea diagnosis. The market value includes the value of related goods sold by the service provider or included within the service offering. The neurodiagnostic market consists of sales of transcranial magnetic stimulation (TMS) devices, magnetoencephalography (MEG) systems, polysomnography (PSG) devices, and biosensors. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.